We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Current status and progress of PD-L1 detection: guiding immunotherapy for non-small cell lung cancer.
- Authors
Qi, Chang; Li, Yalun; Zeng, Hao; Wei, Qi; Tan, Sihan; Zhang, Yuanyuan; Li, Weimin; Tian, Panwen
- Abstract
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths and represents a substantial disease burden worldwide. Immune checkpoint inhibitors combined with chemotherapy are the standard first-line therapy for advanced NSCLC without driver mutations. Programmed death-ligand 1 (PD-L1) is currently the only approved immunotherapy marker. PD-L1 detection methods are diverse and have developed rapidly in recent years, such as improved immunohistochemical detection methods, the application of liquid biopsy in PD-L1 detection, genetic testing, radionuclide imaging, and the use of machine learning methods to construct PD-L1 prediction models. This review focuses on the detection methods and challenges of PD-L1 from different sources, and discusses the influencing factors of PD-L1 detection and the value of combined biomarkers. Provide support for clinical screening of immunotherapy-advantage groups and formulation of personalized treatment decisions.
- Subjects
NON-small-cell lung carcinoma; PROGRAMMED death-ligand 1; IMMUNE checkpoint inhibitors; RADIONUCLIDE imaging; IMMUNOTHERAPY; NON-communicable diseases
- Publication
Clinical & Experimental Medicine, 2024, Vol 24, Issue 1, p1
- ISSN
1591-8890
- Publication type
Article
- DOI
10.1007/s10238-024-01404-1